pharmaceutical investing Aquestive Therapeutics to Participate in Upcoming March Investor Conferences
pharmaceutical investing Aquestive Therapeutics to Report Fourth Quarter 2025 Financial Results and Recent Business Highlights on March 4 and Host Conference Call on March 5 at 8:00 a.m. ET
pharmaceutical investing Aquestive Therapeutics to Participate in Oppenheimer 36th Annual Healthcare Life Sciences Conference
pharmaceutical investing Aquestive Therapeutics to Present New Clinical Data on Anaphylm Sublingual Film at the 2026 AAAAI Annual Meeting
pharmaceutical investing Aquestive Therapeutics Appoints Internationally Recognized Allergist Dr. Matthew Greenhawt as Chief Medical Officer
pharmaceutical investing Aquestive Therapeutics Announces FDA Issuance of Complete Response Letter for Anaphylm
pharmaceutical investing Aquestive Therapeutics Announces Regulatory Development for Anaphylm Sublingual Film and Provides Business Update
pharmaceutical investing Aquestive Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference
pharmaceutical investing Aquestive Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
pharmaceutical investing Aquestive Therapeutics to Participate in a Fireside Chat Hosted by Piper Sandler
pharmaceutical investing Aquestive Therapeutics to Report Third Quarter 2025 Financial Results and Recent Business Highlights on November 5 and Host Conference Call on November 6 at 8:00 a.m. ET
pharmaceutical investing Aquestive Therapeutics Announces that FDA Will Not Require an Advisory Committee Meeting to Discuss New Drug Application for Anaphylm
Homerun Resources Inc. Signs Commercial Letter of Intent with Jundu Ltda. for the Supply, Extraction and Primary Processing of High-Purity Silica Sand
